CMS121 Catalog No.GC40632

A substituted quinoline with diverse biological activities

Size Price Stock Qty
In stock
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 1353224-53-9 SDF Download SDF
Synonyms N/A
Chemical Name 4-[4-(cyclopentyloxy)-2-quinolinyl]-1,2-benzenediol
Canonical SMILES OC1=CC(C2=NC(C=CC=C3)=C3C(OC4CCCC4)=C2)=CC=C1O
Formula C20H19NO3 M.Wt 321.4
Solubility 20mg/mL in DMSO, 30mg/mL in DMF Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



CMS121 is a substituted quinoline that has neuroprotective, anti-inflammatory, antioxidative, and renoprotective activities.[1][2][3] It maintains glutathione (GSH) levels in HT22 mouse hippocampal cells in vitro in the presence of glutamate, induces differentiation of PC12 cells, prevents LPS-induced N9 microglial activation by 82% in N9 microglia, and scavenges free radicals in a Trolox equivalent activity concentration (TEAC) assay.[1] CMS121 protects against ischemia and oxytosis in phenotypic screens in HT22 cells in vitro with EC50 values of 7 and 200 nM for preventing iodoacetic acid- or glutamate-induced cell death, respectively.[2]  It is also renoprotective, decreasing kidney weight loss and decreasing the expression of TNF-α, caspase-1, and inducible nitric oxide synthase (iNOS) in a SAMP8 mouse model of chronic kidney disease associated with rapid aging when administered at a dose of 10 mg/kg per day starting at nine months of age.[3]

[1]. Chiruta, C., Schubert, D., Dargusch, R., et al. Chemical modification of the multi-target neuroprotective compound fisetin. J. Med. Chem. 55(1), 378-389 (2012).
[2]. Prior, M., Chiruta, C., Currais, A., et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 5(7), 503-513 (2014).
[3]. Currais, A., Maher, P., Schubert, D., et al. Prevention and treatment of aging and neurodegenerative diseases. (2017).